Amgen Stock Climbs 4.34% Following Positive Trial News

Amgen's stock price rose by 4.34 percent on September 23, 2026, closing at $410.24 on the Nasdaq.

This gain contrasted with a decline of 1.13 percent in the Nasdaq Composite to 26,936.04 points.

The company's stock traded between $398.53 and $412.76, with about 3.55 million shares recorded on September 23, 2026.

This move was driven by positive late-stage trial news for dazodalibep in Sjogren disease and a higher price target from Jefferies, which raised its target to $410.00 after the experimental treatment met its primary late-stage trial goal.